# myDC/pDC in Stage III Melanoma Patients

> **NCT02574377** · PHASE1,PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** A: myDC vaccination
- **DRUG:** B: pDC vaccination
- **DRUG:** C: combined myDC/pDC vaccination

## Key facts

- **NCT ID:** NCT02574377
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574377, "myDC/pDC in Stage III Melanoma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02574377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*